Evidence map›Paper›PMID 39797229›Full record

ArticleJournal of clinical medicine2024

Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project).

Eduard Fort-Casamartina, Sonia Pernas, Sara Otero, Paula Mate, Núria Gonzalo, Sonia Narváez, Raúl Rigo-Bonnin, Ariadna Padró-Miquel, Àlex Teulé, Xavier Garcia Del Muro and 8 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Rifabutin for Rhodococcus hoagii Pulmonary Abscess in a Cancer Patient on Everolimus.Transplant infectious disease : an official journal of the Transplantation Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Eduard Fort-CasamartinaPharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Sonia PernasMedical Oncology Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-1485-5080
Sara OteroPharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-8166-1163
Paula MatePharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Núria GonzaloPharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Sonia NarváezPharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Raúl Rigo-BonninLaboratory of Molecular Genetics, Laboratori Clínic Territorial Metropolitana Sud, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L' Hospitalet Llobregat, 08908 Barcelona, Spain.ORCID 0000-0001-5511-074X
Ariadna Padró-MiquelLaboratory of Molecular Genetics, Laboratori Clínic Territorial Metropolitana Sud, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L' Hospitalet Llobregat, 08908 Barcelona, Spain.ORCID 0000-0002-6488-447X
Àlex TeuléMedical Oncology Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Xavier Garcia Del MuroMedical Oncology Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Inma PeiróClinical Nutrition Unit, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, University of Barcelona, 08908 Barcelona, Spain.
Lorena ArribasClinical Nutrition Unit, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, University of Barcelona, 08908 Barcelona, Spain.ORCID 0000-0002-9683-9999
Anna EsteveMedical Oncology Department, Institut Català Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute (IGTP), 08916 Badalona, Spain.ORCID 0000-0002-1962-971X
Andrea GonzalezMedical Oncology Department, Institut Català Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute (IGTP), 08916 Badalona, Spain.ORCID 0009-0005-4236-0199
Montse ReyPharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Ana ClopésCatSalut Medicine Area Director, 08028 Barcelona, Spain.
Sandra FontanalsPharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.
Carme MuñozPharmacy Department, Institut Català Oncologia (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet Llobregat, 08908 Barcelona, Spain.

Funding

Sociedad Española de Farmacia Hospitalaria 644/2024
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancereverolimusoptimal dosagepharmacokinetic variabilitytherapeutic drug monitoring

Identifiers

PMID39797229
PMCPMC11721870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.